The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2019

Filed:

Jan. 30, 2017
Applicant:

Novazoi Theranostics, Rolling Hills Estates, CA (US);

Inventors:

Ritu Aneja, Lilburn, GA (US);

Padmashree C. G. Rida, Plano, TX (US);

Assignee:

NOVAZOI THERANOSTICS, Rancho Palos Verdes, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G06K 9/00 (2006.01); G06F 19/20 (2011.01); G01N 33/574 (2006.01); G16H 50/30 (2018.01); A61K 31/343 (2006.01); A61K 31/365 (2006.01); A61K 31/473 (2006.01); G01N 33/58 (2006.01); G06F 19/18 (2011.01); G06F 19/00 (2018.01);
U.S. Cl.
CPC ...
G06F 19/20 (2013.01); A61K 31/343 (2013.01); A61K 31/365 (2013.01); A61K 31/473 (2013.01); G01N 33/57407 (2013.01); G01N 33/57415 (2013.01); G01N 33/57438 (2013.01); G01N 33/57496 (2013.01); G01N 33/582 (2013.01); G06F 19/00 (2013.01); G06F 19/18 (2013.01); G16H 50/30 (2018.01);
Abstract

A method of computing the risk profile of a neoplastic tissue in a patient is disclosed. The method includes the steps of (a) processing a sample of tumor tissue or cancer cells from the patient in a form suitable for visualization and demarcation of cell nuclei, individually distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs) in a region of interest (ROI) defined by a plurality of cell nuclei; (b) determining the numbers of iCTRs and mCTRs associated with each cell nucleus in the ROI; (c) determining the volume of each iCTR and mCTR in the ROI; and (d) calculating one or more centrosome amplification scores (CASs) values for the sample based on steps (b) and (c), wherein the one or more CASs indicate the severity of centrosome amplification, the frequency of centrosome amplification, or both, and wherein the one or more scores provide a measure of a level of risk and/or a prognosis associated with the neoplastic tissue.


Find Patent Forward Citations

Loading…